Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA II: Nivolumab Induction in HPV+ Oropharyngeal Cancer
NCT03107182Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jun 2017
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in oropharyngeal squamous cell carcinoma (OPSCC) (4 arms), sponsored by University of Chicago. Primary endpoint: Deep Response Rate at 24 months. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03107182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107182.